Core Viewpoint - In 2025, the professional health insurance market is undergoing a deep adjustment amid slowing industry growth, intensified competition, and upgraded demand. Fosun United Health Insurance is focusing on the "insurance + medical + health management" strategy, achieving breakthroughs in scale and profitability, demonstrating resilience and vitality in high-quality growth, and injecting new momentum into the industry's transformation [1] Group 1: Performance and Financials - In 2025, the company's insurance business revenue reached 7.84 billion, a year-on-year increase of 50%, ranking among the top in growth among professional health insurance companies [2] - The company achieved a net profit of 130 million, marking five consecutive years of profitability, reflecting continuous optimization in operational efficiency and resource integration [2] - By the end of 2025, the company's total asset scale reached 24.1 billion, with net assets of 3 billion, further enhancing its capital strength [2] Group 2: Product Innovation - The company launched the industry's first full lifecycle managed critical illness insurance "Rui Xing Bao" in collaboration with Ruijin Hospital, focusing on "health management in advance" [3] - This product integrates insurance protection with professional medical services, utilizing smart wearable devices and the "Rui Bao Health" app to create a comprehensive health support system covering prevention, diagnosis, and rehabilitation [3] - The innovation shifts insurance services from "post-event compensation" to "proactive management," enhancing the professionalism and credibility of health insurance services through the empowerment of public medical resources [3] Group 3: Capital Strength - In September 2025, the company completed a strategic capital increase of 810 million, raising its registered capital to 1.01085 billion, and successfully introduced international strategic investors such as the International Finance Corporation (IFC) and the Asian Development Bank (ADB) [4] - The diversified shareholder structure brings international risk control concepts, project experience in the health sector, and medical ecosystem resources, further strengthening the synergy of "insurance + medical" [4] - By the fourth quarter of 2025, the company's core solvency adequacy ratio reached 121.05%, and the comprehensive solvency adequacy ratio reached 173.25%, significantly enhancing its capital strength to support business expansion and innovation [4] Group 4: Investment Capability - The company adheres to a long-term value investment philosophy, constructing a portfolio primarily composed of liquid and fixed-income assets, with moderate equity asset allocation [5] - The average investment return rate over the past three years reached 5.08%, and the average comprehensive investment return rate reached 7.09%, placing it at the leading level in the industry [5] - This demonstrates the company's ability to navigate through cycles, providing stable support for profit growth and customer protection [5] Group 5: Ecosystem Collaboration - The achievements in 2025 stem from the company's continuous deepening of the "insurance + medical + health management" ecosystem strategy [6] - The company aims to leverage its capital strength, service capabilities, and ecological layout to actively respond to the "Healthy China 2030" strategy, focusing on inclusive insurance, grassroots health coverage, chronic disease management, and elderly care [6] - The company seeks to contribute to the construction of a national health security system through innovative services and ecosystem collaboration [6]

Core Insights - The company reflects on a year of significant achievements in the biopharmaceutical sector, highlighting the successful clinical use of its innovative drug, Revamin, and the approval of multiple CAR-T products, showcasing its commitment to addressing rare diseases and cancer treatment gaps [3][6][33] - Club Med has seen substantial growth, with global revenue projected to increase from €1.5 billion in 2015 to €2.1 billion in 2024, and operating profit has grown over five times, indicating strong market demand for innovative travel experiences [9][40] - The company emphasizes its focus on user-centered product development in the tourism sector, aiming to enhance family vacation experiences rather than merely creating tourist attractions [6][38] Biopharmaceutical Innovations - Revamin has been officially launched for clinical use, filling a treatment void for rare tumors in China [3][7] - The company has successfully developed and received approval for multiple innovative drugs, including the first CAR-T product for gastric cancer, which has been recognized as a breakthrough therapy [6][38] - Since 2019, the company has launched a total of 12 innovative drugs, demonstrating its ongoing commitment to patient care and treatment advancements [3][33] Tourism and Leisure Sector - Club Med's performance has reached new heights, with an increasing number of families prioritizing snow vacations, supported by the ongoing development of the "Super Mediterranean" project [6][38] - The company has introduced three core product lines in the tourism sector, focusing on user needs to enhance vacation experiences [6][38] - Atlantis in Sanya has solidified its leading position in the vacation market, with annual visitor numbers reaching 1.5 million [11][43] Globalization and Market Expansion - The company has achieved over 50% of its revenue from international markets, highlighting its successful globalization strategy [16][45] - The Portuguese insurance subsidiary has seen nearly 30% of its business come from international operations, contributing to a diversified revenue stream [16][45] - The company has established strategic partnerships, such as with Fakeeh Care Group in Saudi Arabia, to expand its CAR-T technology internationally [16][46] Cultural and Community Engagement - The company has actively engaged in cultural initiatives, such as the successful summer event at Yuyuan Garden, attracting over 7.5 million visitors, with a significant portion being young people [52] - The company has been recognized for its commitment to social responsibility, being included in the S&P Global Sustainability Yearbook for the second consecutive year [54] - Ongoing support for educational and healthcare initiatives, including donations to Fudan University Affiliated Hospital, reflects the company's dedication to community welfare [57]